DUBLIN–(BUSINESS WIRE)–The “Desmoid Tumors – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.
This pipeline report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Desmoid Tumors pipeline landscape.
This report provides an in-depth analysis of the Desmoid Tumors pipeline, covering both clinical and nonclinical stage products. It assesses therapeutics across various parameters such as product type, stage of development, route of administration, and molecule type. Additionally, the report highlights inactive pipeline products in this area.
The report offers comprehensive insights into the current scenario and growth prospects within the Desmoid Tumors indication. It provides a detailed overview of the disease and offers treatment guidelines for Desmoid Tumors.
The assessment section of the report includes a thorough commercial evaluation and clinical assessment of the pipeline products in development. Each drug is described in detail, including its mechanism of action, clinical studies, NDA approvals (if applicable), and product development activities. This section also covers technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details.
Companies and academic institutions are actively working to assess challenges and identify opportunities that could impact the research and development of therapies for Desmoid Tumors. The therapies currently under development aim to explore novel approaches to treat and improve the management of Desmoid Tumors.
Desmoid Tumors Emerging Drugs Chapters
This segment of the Desmoid Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Desmoid Tumors Emerging Drugs
Nirogacestat: SpringWorks Therapeutics
Nirogacestat is an oral, selective, small molecule, gamma secretase inhibitor. It is currently in NDA phase of clinical development for patients with desmoid tumors. Desmoid tumors are rare and often debilitating and disfiguring soft tissue tumors for which there are currently no FDA-approved therapies.
SpringWorks has a New Drug Application (NDA) under review by the FDA for nirogacestat for the treatment of adults with desmoid tumors, which is being reviewed under the FDA’s Real-Time Oncology Review (RTOR) program. Nirogacestat has received Orphan Drug Designation, Fast Track and Breakthrough Therapy Designations for this indication.
Tegavivint: Iterion Therapeutics
Tegavivint is a potent and selective inhibitor of nuclear b-catenin that binds to TBL1 (Transducin beta-like Protein One). This enables specific silencing of Wnt-pathway oncogenic gene expression without affecting other necessary cellular functions and thus avoids toxicity issues common to other drugs in this pathway. Tegavivint is currently in Phase IIa clinical trial in progressive desmoid tumors after establishing safety and initial clinical efficacy in Phase I study.
Desmoid Tumors: Therapeutic Assessment
This segment of the report provides insights about the different Desmoid Tumors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Desmoid Tumors
There are approx. 12+ key companies which are developing the therapies for Desmoid Tumors. The companies which have their Desmoid Tumors drug candidates in the most advanced stage, i.e. NDA include, SpringWorks Therapeutics.
Desmoid Tumors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Desmoid Tumors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Desmoid Tumors drugs.
Key Questions Answered
- How many companies are developing Desmoid Tumors drugs?
- How many Desmoid Tumors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Desmoid Tumors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Desmoid Tumors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Desmoid Tumors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Ayala Pharmaceuticals, Inc,
- SpringWorks Therapeutics
- Recursion Pharmaceuticals Inc.
- Iterion Therapeutics
- 180 Life Sciences
- AFT Pharma
- Timber Pharmaceuticals
- MedPact
- Intas Pharmaceutical
- Jina pharmaceuticals
Key Products
- AL102
- Nirogacestat oral tablet
- REC-4881
- Tegavivint
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Desmoid Tumors Report Insights
- Desmoid Tumors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Desmoid Tumors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/98ncqv.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900